Fort Myers-based oncology testing services company NeoGenomics announced it will appeal a preliminary injunction issued by the U.S. District Court for the Middle District of North Carolina. The court’s initial determination was that Texas-based testing company Natera Inc. demonstrated a likelihood that products using NeoGenomics’ RaDaR technology, a liquid biopsy test for the detection of minimal or molecular residual disease, infringe on a Natera patent. The order specifically allows patients already using RaDaR to continue their use. In addition, the order explicitly allows research projects and studies that are in progress, as well as clinical trials that are in progress or have been approved, to continue. Chris Smith, CEO of NeoGenomics, said the company plans to appeal the ruling.
Ave Maria welcomed many new restaurants and retailers to its Collier County community in 2024. Many of the newcomers launched...
Read more